CN116438182A - 用于抑制bcr-abl酪氨酸激酶的7-氮杂吲哚化合物 - Google Patents

用于抑制bcr-abl酪氨酸激酶的7-氮杂吲哚化合物 Download PDF

Info

Publication number
CN116438182A
CN116438182A CN202180081403.1A CN202180081403A CN116438182A CN 116438182 A CN116438182 A CN 116438182A CN 202180081403 A CN202180081403 A CN 202180081403A CN 116438182 A CN116438182 A CN 116438182A
Authority
CN
China
Prior art keywords
alkylene
alkyl
independently
cycloalkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180081403.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·P·利西甲托斯
S·金兹
任力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitality Therapy Co
Original Assignee
Vitality Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitality Therapy Co filed Critical Vitality Therapy Co
Publication of CN116438182A publication Critical patent/CN116438182A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180081403.1A 2020-10-05 2021-10-04 用于抑制bcr-abl酪氨酸激酶的7-氮杂吲哚化合物 Pending CN116438182A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063087780P 2020-10-05 2020-10-05
US63/087,780 2020-10-05
PCT/US2021/071692 WO2022076973A1 (en) 2020-10-05 2021-10-04 7-azaindole compounds for inhibition of bcr-abl tyrosine kinases

Publications (1)

Publication Number Publication Date
CN116438182A true CN116438182A (zh) 2023-07-14

Family

ID=81125544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180081403.1A Pending CN116438182A (zh) 2020-10-05 2021-10-04 用于抑制bcr-abl酪氨酸激酶的7-氮杂吲哚化合物

Country Status (8)

Country Link
US (1) US20240043420A1 (enExample)
EP (1) EP4225741A4 (enExample)
JP (1) JP7826325B2 (enExample)
KR (1) KR20230104782A (enExample)
CN (1) CN116438182A (enExample)
IL (1) IL301740A (enExample)
MX (1) MX2023003996A (enExample)
WO (1) WO2022076973A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118791413A (zh) * 2024-06-18 2024-10-18 青岛润农化工有限公司 一种丁醚脲的合成方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3196620A1 (en) 2020-10-05 2022-04-14 Enliven Therapeutics, Inc. 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases
WO2023081637A1 (en) * 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
CN116063212B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种4-苯硫基-1,2-苯二胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
JP5122280B2 (ja) 2004-06-30 2013-01-16 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼのインヒビターとして有用なアザインドール
EP2325184A1 (en) * 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP2007099640A (ja) 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
FR2941948B1 (fr) * 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
FR3000492B1 (fr) * 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
US10696687B2 (en) * 2015-08-20 2020-06-30 Changzhou Jiekai Pharmatech Co., Ltd. Pyrazolo fused heterocyclic compounds as ERK inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118791413A (zh) * 2024-06-18 2024-10-18 青岛润农化工有限公司 一种丁醚脲的合成方法

Also Published As

Publication number Publication date
KR20230104782A (ko) 2023-07-10
WO2022076973A1 (en) 2022-04-14
US20240043420A1 (en) 2024-02-08
IL301740A (en) 2023-05-01
EP4225741A4 (en) 2024-10-30
EP4225741A1 (en) 2023-08-16
JP7826325B2 (ja) 2026-03-09
JP2023545219A (ja) 2023-10-26
MX2023003996A (es) 2023-06-15

Similar Documents

Publication Publication Date Title
CN113557235B (zh) 用于药物治疗的杂环化合物
JP6577613B2 (ja) キナーゼ阻害剤としての縮合環式または三環式アリールピリミジン化合物
JP7826325B2 (ja) Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための７－アザインドール化合物
KR20200011965A (ko) Map4k1의 신규한 억제제
EA035499B1 (ru) Новые ингибиторы глутаминазы
JP2022526854A (ja) ホスファチジルイノシトール３－キナーゼ阻害剤
CA3107365A1 (en) Pyrazine compounds and uses thereof
CA3116141C (en) Cycloalkane-1,3-diamine derivative
CN119019388B (zh) 用于抑制Bcr-Abl酪氨酸激酶的5-和6-氮杂吲哚化合物
CA3096732A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
EP3600287A1 (en) Inhibitors of kinase networks and uses thereof
CN121013849A (zh) 作为wrn抑制剂的杂环化合物
CN118184639A (zh) Gspt1降解剂及其应用
CN113387962A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CA3231988A1 (en) Azaindazole macrocycle compound and use thereof
JP2025527170A (ja) アミノヘテロアリールキナーゼ阻害剤
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
JP2024535867A (ja) 治療薬としてｎ－アリールピリミジン－２－アミン誘導体を有する化合物
TW202214634A (zh) 雜環化合物及其衍生物
AU2022305807B2 (en) Pyrimidine compounds for use as map4k1 inhibitors
CN116648453A (zh) 用于抑制Bcr-Abl酪氨酸激酶的5-和6-氮杂吲哚化合物
CN120390740A (zh) 作为PI3Kα抑制剂的杂环化合物
CN120129682A (zh) 用于抑制raf激酶的萘啶化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: Colorado, USA

Applicant after: Yingleiwen Co.

Address before: Colorado, USA

Applicant before: Vitality Therapy Co.

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: California, USA

Applicant after: Yingleiwen Co.

Address before: Colorado, USA

Applicant before: Yingleiwen Co.

Country or region before: U.S.A.

CB02 Change of applicant information